In conversation with Eric Esser, President and Chief Executive Officer, Telesis Bio

While the pace of dealmaking in the infectious diseases field has declined considerably from its peak during the COVID-19 pandemic, leading vaccine companies have still been signing major deals.

Over the past year, AI-focused biopharma collaborations have increasingly attracted large upfront payments and extended their reach outside of small molecule drug discovery.

A review of upcoming drug launches, patent expiries, and pivotal trials, according to analysts at AdisInsight.

NEOsphere Biotechnologies is accelerating drug discovery through high-throughput proteomics, enabling efficient screening of molecular glue libraries and systematic identification of clinically relevant degraders.

Defence Therapeutics’ proprietary Accum technology platform reduces the half-maximal inhibitory concentration (IC50) of antibody–drug conjugates up to fifty-fold by solving the endosome-entrapment problem.

In conversation with Brian Markison, CEO, Lantheus

The government-funded organization supports Korean biotech and pharma companies in more than 100 pipelines annually to discover, develop and test the most promising therapeutic candidates.

The clinical success of biologics is often hindered by a lack of safe, targeted delivery systems. SiVEC Biotechnologies aims to change this with its groundbreaking BactPac platform.

Ability Biotherapeutics is developing next-generation immune-modulating therapies for cancer and autoimmune diseases.

Transcenta is employing its unique, cutting-edge discovery technology to develop antibody-based therapies that address unmet medical needs in oncology, immunology and inflammation.

Bio-Sourcing is developing innovative solutions that combine cutting-edge gene-editing and nuclear-transfer technologies to up-scale the production of biopharmaceuticals while lowering carbon emissions and costs.

In conversation with Cheryl Ball, Senior VP of Strategy and Corporate Development, Lantheus